RxDoctor Payments Data

Orlando Fuschetto, MD

Interventional Cardiology · Brooklyn, NYNPI 1659518694

Payments from drug & device makers

$4,006in general payments, 2019–2025

Across 98 payments — averaging $40.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Medtronic$406
  • Johnson & Johnson$389
  • Shockwave Medical, Inc$352
  • Boehringer Ingelheim$234
  • AstraZeneca$182
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,95299%
  • Education$551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,006 in reported general payments places this provider in the 25th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$969,306
Medicare patients
1,006
Services billed
8,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban166$202,388
XareltoRivaroxaban66$67,368
BrilintaTicagrelor52$35,709
EntrestoSacubitril/Valsartan22$19,967
Metoprolol Succinate238$3,294
Atorvastatin Calcium148$1,471
ClopidogrelClopidogrel Bisulfate82$1,113
Metoprolol Tartrate126$1,083
Digoxin41$772
Furosemide145$742
Carvedilol60$677
Losartan Potassium86$668
Pantoprazole Sodium47$632
Nifedipine ErNifedipine21$619
Torsemide48$608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$202,388166 claims
Johnson & JohnsonXarelto$389$67,36866 claims
AstraZenecaBrilinta$182$35,70952 claims
NovartisEntresto$153$19,96722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →